1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. France >
  5. EA Pharma Acquires Labcatal

M&A Deal Summary

EA Pharma Acquires Labcatal

On February 14, 2020, EA Pharma acquired life science company Labcatal

Acquisition Highlights
  • This is EA Pharma’s 1st transaction in the Life Science sector.
  • This is EA Pharma’s 1st transaction in France.

M&A Deal Summary
Date 2020-02-14
Target Labcatal
Sector Life Science
Buyer(s) EA Pharma
Deal Type Add-on Acquisition

Target

Labcatal

Cedex, France
Labcatal is a French laboratory specializing in oligotherapy that develops, shapes and markets two major categories of products formulated with trace elements from pharmacies, A range of medicines and food supplements (under its flagship brand Oligosol) and A range of dermatological drugs (Rubozinc and LithioDerm).

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

EA Pharma

Vallauris, France
Category Company
Founded 2006
Sector Life Science
Revenue 40M EUR (2014)
DESCRIPTION

EA Pharma is a pharmaceutical company specialized in production and distribution of drugs, food supplements, and cosmetics. EA Pharma was formed in 2006 and is based in Vallauris, France.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: France M&A 1 of 1
Year: 2020 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal